This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Analysts Estimate Luminex (LMNX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Luminex (LMNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Retail Pharmacy USA Lift Walgreens' (WBA) Q2 Earnings?
by Zacks Equity Research
Widening pharmacy network, healthy prescription volumes along with contributions from Rite Aid are expected to contribute to Walgreens Boots' (WBA) top line in the fiscal second quarter.
Luminex (LMNX) Down 2.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Luminex Hurt By Segmental Sluggishness, Stiff Competition
by Zacks Equity Research
Luminex's (LMNX) dependence on its partners for revenue generation is a major problem.
Luminex (LMNX) Q4 Earnings Miss, 2019 Guidance Lacks Luster
by Zacks Equity Research
Luminex (LMNX) gains from core Consumable unit's strong fourth-quarter show.
Luminex (LMNX) Q4 Earnings Miss Estimates
by Zacks Equity Research
Luminex (LMNX) delivered earnings and revenue surprises of -66.67% and 2.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Luminex (LMNX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Luminex (LMNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Luminex's (LMNX) Preliminary Q4 Results Cheer Investors
by Zacks Equity Research
Luminex (LMNX) likely to gain from strong segmental contributions in Q4.
Here's Why Investors Should Hold Luminex (LMNX) Stock Now
by Zacks Equity Research
Luminex (LMNX) gains from strength in the Aries platform. However, cutthroat competition in the life sciences industry is worrisome.
LMNX or PACB: Which is a Better MedTech Investment Pick?
by Zacks Equity Research
Luminex (LMNX) scores higher than Pacific Biosciences (PACB) considering growth projections and fundamentals.